MegatrendsMegatrends: not the usual suspects, but who actually profits.View megatrends →
Log inStart for free
Create watchlist

NuCana Stock

NuCana plc

NCNANASDAQMarkt
US$0.99
-2.9% today
Analyze stock

Company data

Sector
Healthcare
Industry
Biotechnology
Country
United Kingdom
CEO
Hugh Stephen Griffith
Employees
11
Market cap
$6 M
IPO
28/09/2017

NuCana plc is a clinical-stage biopharmaceutical firm dedicated to pioneering advanced therapies for oncology. Its innovative product pipeline is underpinned by a proprietary ProTide technology platform. Among its key drug candidates, Acelarin is progressing through multiple clinical evaluations: a Phase I study for…

NuCana stock: price history

16/10/25-80.7 %16/10/26

1D

-2.9%

1W

-10.0%

1M

-23.8%

6M

-56.0%

YTD

-72.5%

1Y

-80.7%

2Y

-99.7%

5Y

-100.0%

10Y

–

Next earnings date

Next earnings date

12/11/2026 (in 26 days)

Volatility around earnings

~27% stronger price swings than usual

Ask the agents about NuCana

Analyst assessment of NuCana

0

STRONG BUY

7

BUY

1

HOLD

0

SELL

0

STRONG SELL

8

TOTAL · Buy

As of: 19/08/2024

ANALYST FIRMRATINGACTIONDATE
OppenheimerOutperformmaintain19/08/2024 (older than 12 months)
OppenheimerOutperformmaintain23/07/2024 (older than 12 months)
OppenheimerOutperformmaintain22/07/2024 (older than 12 months)
OppenheimerOutperformmaintain01/04/2024 (older than 12 months)
OppenheimerOutperformmaintain21/11/2023 (older than 12 months)
Truist SecuritiesBuymaintain06/09/2023 (older than 12 months)
OppenheimerOutperformmaintain18/08/2023 (older than 12 months)
OppenheimerOutperformmaintain22/05/2023 (older than 12 months)

NuCana stock metrics

P/E

-0.25

P/B

0.15

EV/EBITDA

0.99

RETURN ON EQUITY

-15.4%

NET MARGIN

0.0%

DEBT/EQUITY

0.03

DIVIDEND YIELD

0.0%

AS OF

30/06/2026

Free float & liquidity

FREE FLOAT

94.1%

FLOAT SHARES

5,714,677

AVG. DAILY VOLUME (30D)

179,554

Institutional holders

FUND / INSTITUTIONSHARESCHANGEAS OF
Abingworth LLP3,333,333+031/12/2022 (older than 12 months)
LADENBURG THALMANN FINANCIAL SERVICES INC.100+10031/12/2019 (older than 12 months)
SUNTRUST BANKS INC70,100+030/09/2019 (older than 12 months)
Woodford Investment Management Ltd0-2,118,00030/09/2019 (older than 12 months)
Sofinnova Management VIII, L.L.C.4,666,666+4,000,00031/12/2017 (older than 12 months)
Page 1 / 2

Dividends & Stock splits

DATERATIO
08/08/20251:200
16/04/20241:25

Comparable stocks

Frequently asked questions about NuCana stock

What does NuCana do?

NuCana plc is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.

The CEO is Hugh Stephen Griffith, the company employs around 11 people.

The IPO was on 28/09/2017; the stock trades on NASDAQ under the ticker NCNA.

What do analysts say about NuCana stock?

8 analysts rate the stock, the consensus is Buy (as of 19/08/2024).

This is an external assessment, not a statement by Market Jury.

When does NuCana report next?

The next earnings date is 12/11/2026.

Around past earnings, price swings were roughly 27% stronger than usual.

Does NuCana pay a dividend?

No, NuCana currently does not pay a dividend.

Which stocks are comparable to NuCana?

Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.

How can I get NuCana stock analyzed?

Clicking "Analyze stock" lets five strategies assess NuCana against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.

Not investment advice. Past performance is not an indicator of future results.